Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 5:02 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 5:02 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Zacks News
Moving Average Crossover Alert: Akebia (AKBA)
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
by Zacks Equity Research
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?
by Zacks Equity Research
Akebia Therapeutics (AKBA) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist
by Zacks Equity Research
On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).
Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics Inc (AKBA).
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Top Ranked Momentum Stocks to Buy for December 28th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, December 28th: